Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease
Esther Meijer(University Medical Center Groningen), Monique Losekoot(Leiden University Medical Center), Michelle J. Pena(University Medical Center Groningen), Dorien J.M. Peters(Leiden University Medical Center), Jack F.M. Wetzels(Radboud University Nijmegen), Hedwig M. A. D‘Agnolo(Radboud University Medical Center), A. Lianne Messchendorp(University Medical Center Groningen), Folkert W. Visser(Ziekenhuis Groep Twente), Edwin M. Spithoven(University Medical Center Groningen), Shosha E.I. Dekker(Leiden University Medical Center), Charles J. Blijdorp(Erasmus MC), Tom J.G. Gevers(Radboud University Medical Center), Marten A. Lantinga(Radboud University Nijmegen), R. Aerts(Radboud University Medical Center), Mahdi Salih(Erasmus MC), Myrte K. Neijenhuis(Radboud University Nijmegen), Darius Soonawala(Haga Hospital), Johan W. de Fijter(Leiden University Medical Center), Robert Zietse(Erasmus MC), Joost P.H. Drenth(Radboud University Nijmegen), Maatje D.A. van Gastel(University Medical Center Groningen), Ron T. Gansevoort, Niek F. Casteleijn(University Medical Center Groningen)
Cited by 105
Related Papers
The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report
|Kidney International|2010|2.3k
World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions
|The Lancet Global Health|2019|1.2k
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k
Clinical practice guideline on diagnosis and treatment of hyponatraemia
|Intensive Care Medicine|2014|1k